Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey M Fowler

Showing results (91-100 of 102) with videos related to

Pageof 11
Sort By:
Obstetrics and Gynecology|May 2, 2007
Clinical and pathologic correlates in surgical stage II endometrial carcinomaDavid E Cohn, Emily M Woeste, Stacey Cacchio, et al.
Surgical Oncology|September 6, 2020
Pathologic chemotherapy response score in epithelial ovarian cancer: Surgical, genetic, and survival considerationsDavid A Barrington, Ashley S Felix, Rieham Owda, et al.
American Journal of Obstetrics and Gynecology|August 5, 2022
Less is more: clinical utility of postoperative laboratory testing following minimally invasive hysterectomy for endometrial cancerMichelle D S Lightfoot, Ashley S Felix, Corinne A Calo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2009
Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumorsPravin T P Kaumaya, Kevin Chu Foy, Joan Garrett, et al.
Gynecologic Oncology|July 16, 2017
Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survivalCasey M Cosgrove, David E Cohn, Heather Hampel, et al.
Gynecologic Oncology|December 14, 2021
Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology studyUrsula A Matulonis, Helen Q Huang, Virginia L Filiaci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2009
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer IntergroupMichael A Bookman, Mark F Brady, William P McGuire, et al.
Gynecologic Oncology|November 28, 2017
Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 StudyNeil S Horowitz, G Larry Maxwell, Austin Miller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2012
Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a gynecologic oncology group studyCharles F Levenback, Shamshad Ali, Robert L Coleman, et al.
Gynecologic Oncology|December 4, 2012
Is bilateral lymphadenectomy for midline squamous carcinoma of the vulva always necessary? An analysis from Gynecologic Oncology Group (GOG) 173Robert L Coleman, Shamshad Ali, Charles F Levenback, et al.
Pageof 11

Showing results (91-100 of 102) with videos related to

Sort By:
Pageof 11
Obstetrics and Gynecology|May 2, 2007
Clinical and pathologic correlates in surgical stage II endometrial carcinomaDavid E Cohn, Emily M Woeste, Stacey Cacchio, et al.
Surgical Oncology|September 6, 2020
Pathologic chemotherapy response score in epithelial ovarian cancer: Surgical, genetic, and survival considerationsDavid A Barrington, Ashley S Felix, Rieham Owda, et al.
American Journal of Obstetrics and Gynecology|August 5, 2022
Less is more: clinical utility of postoperative laboratory testing following minimally invasive hysterectomy for endometrial cancerMichelle D S Lightfoot, Ashley S Felix, Corinne A Calo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2009
Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumorsPravin T P Kaumaya, Kevin Chu Foy, Joan Garrett, et al.
Gynecologic Oncology|July 16, 2017
Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survivalCasey M Cosgrove, David E Cohn, Heather Hampel, et al.
Gynecologic Oncology|December 14, 2021
Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology studyUrsula A Matulonis, Helen Q Huang, Virginia L Filiaci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2009
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer IntergroupMichael A Bookman, Mark F Brady, William P McGuire, et al.
Gynecologic Oncology|November 28, 2017
Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 StudyNeil S Horowitz, G Larry Maxwell, Austin Miller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2012
Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a gynecologic oncology group studyCharles F Levenback, Shamshad Ali, Robert L Coleman, et al.
Gynecologic Oncology|December 4, 2012
Is bilateral lymphadenectomy for midline squamous carcinoma of the vulva always necessary? An analysis from Gynecologic Oncology Group (GOG) 173Robert L Coleman, Shamshad Ali, Charles F Levenback, et al.
Pageof 11